Processa Pharmaceuticals Inc
Veridion Score
BETALOW CONF · 5/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is PCSA moving today?
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
PCSA overview
Related filings and maps
Congress activity in PCSA
No receipt-qualified Congressional disclosure is present for PCSA in the cached public ledger.
PCSA contract awards, year to date.
Public federal awards linked to this ticker.
PCSA lobbying filings, year to date.
Registered lobbying filings matched to Processa Pharmaceuticals Inc.